TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 810648
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with antirheumatic drugs
Study: 810648
Drug: D-penicillamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine and gold treatment
Study: 19222841
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vardenafil administered orally twice a day for 12 weeks
Study: 19222841
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally twice a day for 12 weeks
Study: 11006204
Drug: 1% nitroprusside
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% nitroprusside gel (5 mg)
Study: 11006204
Drug: 2% nitroprusside
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% nitroprusside gel (10 mg)
Study: 9182442
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy with cisplatin, methotrexate, and vinblastine (CMV) after TUR, aiming for vesical preservation (Arm A, n = 20)
Study: 9182442
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with CMV after TUR followed by cystectomy (Arm B, n = 17)
Study: 8374255
Drug: Torasemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (20 mg/day)
Study: 8374255
Drug: Furosemide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (50 mg/day)
Study: 24935075
Drug: Senior work-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senior work-up assessment and treatment (SWAT) model of care
Study: 20541900
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine patches (5, 10, and 20 microg/hour)
Study: 20541900
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (200 and 400 microg tablets)
Study: 18175753
Drug: Daily chocolate
Normalized name: chocolate allergenic extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily chocolate consumption (>=1 time/d)
Study: 10935148
Drug: Neuroleptanalgesia (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptanalgesia (0.025 mg fentanyl and 1.25 mg droperidol)
Study: 10935148
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg initial dose, followed by 5 mg every 4 hours)
Study: 3515526
Drug: Enteric-coated naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated naproxen tablets (500 mg)
Study: 3515526
Drug: Plain naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain naproxen tablets (500 mg)
Study: 27107490
Drug: ICS plus
Normalized name: Nubasics Plus Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS plus theophylline 100 mg bid
Study: 15649831
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (manual acupuncture at Y point on the neck, 4 sessions over 2 weeks)
Study: 2598986
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide (5 mg.h‐1)
Study: 2598986
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion with caerulein (10‐40 ng.kg‐1.h‐1)
Study: 16115390
Drug: Theophylline 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 0.2 g twice a day for one month (group CA)
Study: 31418538
Drug: Rolapitant (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolapitant (single dose range, 9-180 mg)
Study: 28273591
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education intervention for caregivers (initial sessions and monthly monitoring for 6 months)
Study: 21261971
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment of MTrPs including manual compression, manual stretching, intermittent cold application, home exercises, and ergonomic advice.
Study: 21261971
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment of MTrPs.
Study: 27936169
Drug: Control supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control supplements
Study: 11726005
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (25-100 mg/d)
Study: 29649002
Drug: Baricitinib treatment
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib treatment
Study: 27141849
Drug: Chemical 'cold-like'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical 'cold-like' counter-irritation with 40% L-menthol and 10% trans-cinnamaldehyde
Study: 12548508
Drug: Tacrolimus, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus, 20 ng/mL, plus Plasma‐lyte A liver flush solution
Study: 3512622
Drug: Fluspirilene (23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluspirilene (23 mg/week for men, 13 mg/week for women)
Study: 20051119
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual in primary care.
Study: 18978566
Drug: Paclitaxel 230
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 230 mg/m followed by cisplatin 75 mg/m on day 1 every 21 days, with granulocyte colony stimulating factor 5 microg/kg/d beginning on day 3 of each cycle
Study: 12436430
Drug: Decongestive lymphatic
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestive lymphatic therapy (DLT) with adjunctive intermittent pneumatic compression (IPC)
Study: 12436430
Drug: Decongestive lymphatic
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestive lymphatic therapy (DLT) alone
Study: 11874940
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg pioglitazone
Study: 9521337
Drug: Intravenous ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbate (vitamin C)
Study: 26618470
Drug: Calcium Hydroxylapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Hydroxylapatite (CaHA) treatment
Study: 26618470
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment until end of study)
Study: 23551070
Drug: 24 IU
Normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24 IU intranasal oxytocin (OXT)
Study: 16826364
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (400-1,200 IU per day) with calcium (800-1,500 mg per day)
Study: 12627044
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA), 5 mg/day for 14 days (days 12-25)
Study: 12627044
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA), 10 mg/day for 14 days (days 12-25)
Study: 12627044
Drug: Dydrogesterone, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone, 20 mg/day for 14 days (days 12-25)
Study: 8239616
Drug: High-dose mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mefloquine (25 mg/kg)
Study: 8239616
Drug: Conventional mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional mefloquine (15 mg/kg)
Study: 22961024
Drug: Daily disinfection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disinfection of high-touch surfaces
Study: 21041348
Drug: Telehealth intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telehealth intervention (online multifamily psychoeducational therapy)
Study: 21041348
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (treatment as usual)
Study: 16052393
Drug: Dalteparin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (low molecular weight heparin) administered immediately after cesarean section until mobilization
Study: 8746864
Drug: Drug trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug trials conducted by hospitals
Study: 29943518
Drug: Standard Crisis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Crisis Response Plan (treatment as usual)
Study: 26364288
Drug: Continuing clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing clopidogrel 75 mg daily (extended‐dual antiplatelet therapy, DAPT, group)
Study: 26364288
Drug: Discontinuing clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuing clopidogrel (aspirin group)
Study: 26364288
Drug: Continuing clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing clopidogrel 75 mg daily (extended‐DAPT group)
Study: 23035060
Drug: Bilateral arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral arm ischemic preconditioning (BAIPC), 5 brief cycles of ischemia followed by reperfusion, performed twice daily over 300 days.
Study: 18846366
Drug: Alcohol (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (low dose: 0.12 g/kg for women, 0.14 g/kg for men)
Study: 18846366
Drug: Alcohol (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (high dose: 0.37 g/kg for women, 0.42 g/kg for men)
Study: 18437797
Drug: Early placed
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early placed implants
Study: 11586014
Drug: Combination product
Normalized name: Drug-device combination product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination product of calcipotriol and betamethasone dipropionate
Study: 11586014
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments except for the vehicle
Study: 9676347
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release pellets (500 mg theophylline)
Study: 9676347
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion (350 mg theophylline over 8 h)
Study: 31997236
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) treatment with Huoxue Xiaoyi Granule before ovulation and Bushen Zhuyun Granule after ovulation for 6 menstrual cycles.
Study: 31997236
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control group receiving placebo treatment for 6 menstrual cycles.
Study: 31997236
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) treatment.
Study: 25231512
Drug: ACT-280778 10
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-280778 10 mg
Study: 19546359
Drug: Weekly L-AMB
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly L-AMB dosing (7.5 mg/kg)
Study: 19546359
Drug: Single L-AMB
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single L-AMB dose (15 mg/kg)
Study: 19546359
Drug: Daily L-AMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily L-AMB dosing (1 mg/kg)
Study: 19546359
Drug: Overall infusion-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall infusion-related reactions
Study: 18322594
Drug: 90 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 micrograms recombinant hepatitis B vaccine + IFN alpha 1b 50 micrograms 3 times a week for 24 weeks
Study: 18322594
Drug: 60 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 micrograms recombinant hepatitis B vaccine + IFN alpha 1b 50 micrograms 3 times a week for 24 weeks
Study: 8549061
Drug: Acute caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute caffeine ingestion (250 mg)
Study: 28277054
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for erythema migrans (specific regimens not detailed in the abstract)
Study: 28277054
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for erythema migrans
Study: 23835707
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m² on day 1 of 21-day cycles; n = 359)
Study: 21736786
Drug: Exercise-induced dehydration
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise-induced dehydration plus a diuretic (DD; 40 mg furosemide)
Study: 19756431
Drug: Response evaluation
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response evaluation or prediction after neoadjuvant chemotherapy
Study: 22541039
Drug: Treatment responders
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment responders
Study: 15305227
Drug: 1,000 mU/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mU/l prolactin
Study: 15305227
Drug: 100 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ng/ml leptin
Study: 24769014
Drug: Lenalidomide (LEN)
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide (LEN) maintenance therapy, 10 mg daily, given on days 1 to 21 of 28-day cycles for 12 months after alloHCT.
Study: 19948383
Drug: Oxycodone 20mg
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 20mg
Study: 19948383
Drug: Oxycodone 0mg
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 0mg (placebo)
Study: 11888836
Drug: Two daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two daily subcutaneous injections of hexarelin (1.5 microg/kg)
Study: 11888836
Drug: Three daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three daily subcutaneous injections of hexarelin (1.5 microg/kg)
Study: 11888836
Drug: Intravenous hexarelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hexarelin (1 microg/kg) at the end of each 24-h sampling period
Study: 11888836
Drug: Prior hexarelin
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior hexarelin administration
Study: 10442376
Drug: UFT 300
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 300 mg/m2 plus calcium folinate 90 mg (divided into three doses per day)
Study: 10442376
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel starting at 50 mg/m2, escalated in 10 mg/m2 steps
Study: 8522637
Drug: Xanomeline tartrate
Normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline tartrate 25 mg three times a day
Study: 8522637
Drug: Xanomeline tartrate
Normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline tartrate 35 mg three times a day
Study: 8522637
Drug: Xanomeline tartrate
Normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline tartrate 50 mg three times a day
Study: 8522637
Drug: Xanomeline tartrate
Normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline tartrate 60 mg three times a day
Study: 8522637
Drug: Xanomeline tartrate
Normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline tartrate 75 mg three times a day
Study: 8522637
Drug: Xanomeline tartrate
Normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline tartrate 90 mg three times a day
Study: 8522637
Drug: Xanomeline tartrate
Normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline tartrate 100 mg three times a day
Study: 8522637
Drug: Xanomeline tartrate
Normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline tartrate 115 mg three times a day
Study: 6459255
Drug: HNN cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: HNN cream (halcinonide, neomycin, and nystatin)
Study: 6459255
Drug: BGI cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGI cream (betamethasone valerate, gentamicin, iodochlorhydroxyquin, and tolnaftate)
Study: 6459255
Drug: HNN cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: HNN cream
Study: 6459255
Drug: BGI cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGI cream
Study: 26331880
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration (0.325 g/kg)
Study: 26331880
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration (0.65 g/kg)
Study: 26331880
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration (0.00 g/kg)
Study: 26331880
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration (0.00 g/kg)
Study: 26529118
Drug: Escitalopram 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 30 mg
Study: 19730388
Drug: Escitalopram (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (both doses)
Study: 15190235
Drug: Gabapentin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (up to a maximum dose of 2,400 mg/d in three doses)
Study: 1839998
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral preparation of medroxyprogesterone acetate (200‐mg sachet, twice daily)
Study: 1839998
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation (Farlutal, 500‐mg tablet, twice daily)
Study: 1839998
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral preparation of medroxyprogesterone acetate
Study: 19387901
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockers (ARB) - losartan (25‐50 mg, n = 5), candesartan (4‐8 mg, n = 4), valsartan (80 mg, n = 1), telmisartan (40 mg, n = 2), olmesartan (10 mg, n = 1)
Study: 15293073
Drug: Conventional influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional influenza split vaccine (SpV)
Study: 15293073
Drug: MF59‐adjuvanted subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59‐adjuvanted subunit vaccine (aSuV)
Study: 15293073
Drug: Virosome‐based subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosome‐based subunit vaccine (vSuV)
Study: 3245857
Drug: Bezafibrate sustained
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate sustained release tablet (Cedur retard, 400 mg) taken in the morning
Study: 3245857
Drug: Bezafibrate sustained
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate sustained release tablet (Cedur retard, 400 mg) taken in the evening
Study: 26093863
Drug: High-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statin recapture therapy given orally 12 and 2 hours before CABG
Study: 26093863
Drug: High-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statin recapture therapy
Study: 23732189
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (60 mg/day duloxetine + 300 mg/day pregabalin)
Study: 23732189
Drug: High-dose monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose monotherapy (120 mg/day duloxetine or 600 mg/day pregabalin)
Study: 26816607
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day duloxetine
Study: 22137511
Drug: IV tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV tranexamic acid 10 mg/kg
Study: 22137511
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water 0.1 mL/kg (placebo group)
Study: 2321721
Drug: Caudal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal bupivacaine 0.25% (1 ml/kg)
Study: 2321721
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 0.25 mg/kg
Study: 6985789
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus selective intra‐arterial vasopressin infusion
Study: 21244275
Drug: FD-APAP (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FD-APAP (2 × 500 mg tablets)
Study: 21244275
Drug: Standard acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard acetaminophen (2 × 500 mg tablets)
Study: 19841453
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 500 microg twice daily for 6 months
Study: 19841453
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 500 microg twice daily for 30 months
Study: 19841453
Drug: Fluticasone, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone, 500 microg twice daily, and salmeterol, 50 microg twice daily for 30 months
Study: 17558758
Drug: Phosphatidylcholine-based anti-cellulite
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine-based anti-cellulite gel and LED treatments